Roche Holding Ltd (RO) AI Stock Analysis

Roche Holding Ltd

(Six Swiss:RO)

Select Model

Rating:73Outperform

Price Target:CHF 443.00▲(7.73% Upside)

Action:upgraded

Date:10/24/26

Roche earns an above-average score driven by dependable profitability and best-in-class cash generation that comfortably funds R&D and a rising dividend, alongside a reaffirmed 2026 outlook featuring margin expansion, 9% core EPS growth and strong late-stage pipeline progress. Technicals reinforce the case, with the price trading above all key moving averages in a confirmed uptrend, though the advance has left momentum indicators stretched and a near-term pause is plausible. The main constraints are a premium 25.5x P/E against modest revenue growth, an elevated CHF 31.6B debt load and net debt rising CHF 5.9B, plus identifiable headwinds from China diagnostics pricing reform, biosimilar competition, loss of exclusivity and currency translation.

Positive Factors

Strong profitabilityRoche’s consistently high gross and operating margins indicate substantial earnings power across its pharmaceutical and diagnostics franchises. The sharp 2025 net-margin recovery also shows that profitability can rebound, supporting continued investment in research, launches, and commercial capabilities.

Negative Factors

Loss of exclusivity and competitionPatent expiries, biosimilars, and branded competition can erode revenue from established medicines before replacement products fully scale. The expected CHF 600 million LOE impact creates a recurring need for successful launches, indication expansion, and pipeline execution to protect earnings.

Roche Holding Ltd (RO) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 278.42B
Dividend Yield: 2.63%
Average Volume (3M): 28.38K
Price to Earnings (P/E): 26.3
Beta (1Y): 1.39
Revenue Growth: -1.06%
EPS Growth: 30.86%
Country: Switzerland
Employees: 103,249
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - General

Roche Holding Ltd Business Overview & Revenue Model

Company Description

Roche Holding AG is a global healthcare enterprise with dual focuses: pharmaceuticals and diagnostics. The company maintains a significant presence in numerous countries, including its home base in Switzerland, alongside Germany, the United States, A...

How the Company Makes Money

Roche makes money mainly by selling products from its two operating divisions—Pharmaceuticals and Diagnostics—generating revenue through a combination of direct product sales, recurring consumables, and (to a lesser extent) collaborations and licensi...

Roche Holding Ltd Earnings Call Summary

Earnings Call Date:Jul 22, 2026(Q2-2026)|% Change Since:21.66%|Next Earnings Date:Jan 27, 2027

Earnings Call SentimentPositive

The earnings call presented a predominantly positive financial and operational picture: core operating profit and EPS growth outpaced revenue growth, margins improved, operating cash flow strengthened and the company highlighted strong late‑stage pipeline progress, multiple product launches (including the AXELIOS sequencing platform and CE‑marked assays), five FDA priority reviews and a high Phase III success rate (80% YTD). Material headwinds were acknowledged — notably the China diagnostics pricing reform (Diagnostics down -15% in China), a weak respiratory season (~CHF 200m impact), currency pressure, some competitive and biosimilar effects in specific franchises, a net debt increase (CHF 5.9bn) and impairments affecting IFRS results — but management positioned these as manageable alongside disciplined cost control, reallocation of efficiencies (CHF ~1.3bn) and continued BD activity. On balance, the highlights (strong profitability, pipeline/launch momentum, cash generation and disciplined BD) substantially outweigh the lowlights, supporting a positive outlook for the rest of 2026 and into the next years.

Positive Updates

Core Operating Profit and Margin Expansion

Core operating profit grew +10% year‑over‑year, outpacing sales growth, and core operating margin expanded by +1.7 percentage points, driven by both Pharma (+2.0pp) and Diagnostics (+0.6pp).

Negative Updates

China Diagnostics Pricing Reform Impact

Diagnostics sales in China declined -15% (APAC overall -5%); the China health care pricing reform materially reduced Diagnostics growth and remains a headwind in 2026.

Company Guidance

Roche reiterated full‑year guidance of mid‑single‑digit sales growth and high‑single‑digit core EPS growth (H1: sales +6% overall, Pharma +6% with volumes +9%, Diagnostics +3% or +6% excluding China, China -15%), while confirming core operating profit outperformance (H1 core operating profit +10%, core operating margin +1.7 percentage points) and H1 core EPS +9%; management expects LOE headwinds of roughly CHF 600m in 2026, a H1 core tax rate of 17.5% rising to around ~20% for the full year, and currency headwinds of about -4 ppt on sales and -6 ppt on core operating profit and core EPS, plans to keep Diagnostics margin broadly stable vs. 2025 at ~14.4%, aims for Diagnostics mid‑single‑digit growth in 2026 (mid‑ to high single digits in 2027), will increase dividends in CHF, and notes strong cash performance (operating free cash flow +21%/+2% in CHF, free cash flow +58%/+26% in CHF) alongside a net debt increase of CHF 5.9bn to June (gross debt ~CHF 31.8bn); other revenue is expected to rise from ~3% to ~5% of sales by the end of the decade.

Roche Holding Ltd Financial Statement Overview

Summary

Roche combines strong profitability (≈73% gross margin, ~30% EBIT margin, net margin recovering to 20.9% from 13.3%) with excellent cash generation (CHF 17.8B operating cash flow, CHF 14.1B free cash flow, +11.9% FCF growth and 79% FCF/net income conversion). Offsetting these strengths are a flat-to-slightly-lower revenue base (CHF 62.4B to CHF 61.5B), earnings volatility across years, and an elevated debt load of CHF 31.6B against CHF 33.8B equity, although the debt-to-equity ratio improved to 0.94 from 1.14 and equity has grown steadily since 2021.

Income Statement

72Positive

Balance Sheet

65Positive

Cash Flow

74Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	60.94B	61.52B	62.40B	60.44B	65.81B	62.80B
Gross Profit	44.68B	45.23B	46.11B	44.08B	47.88B	43.10B
EBITDA	21.82B	22.65B	16.62B	18.40B	20.80B	22.19B
Net Income	12.34B	12.88B	8.28B	11.50B	12.42B	13.93B
Balance Sheet
Total Assets	98.20B	100.70B	101.80B	90.47B	88.15B	92.32B
Cash, Cash Equivalents and Short-Term Investments	9.73B	15.48B	17.32B	10.51B	9.77B	13.03B
Total Debt	31.80B	33.19B	36.35B	30.78B	26.54B	32.55B
Total Liabilities	61.48B	62.82B	65.64B	57.20B	56.14B	63.97B
Stockholders Equity	32.69B	33.80B	31.77B	29.32B	27.99B	24.49B
Cash Flow
Free Cash Flow	14.76B	14.08B	15.09B	11.45B	13.34B	16.02B
Operating Cash Flow	18.40B	17.83B	20.09B	16.09B	17.89B	20.57B
Investing Cash Flow	-8.11B	-8.71B	-11.39B	-10.64B	-3.57B	-6.55B
Financing Cash Flow	-12.29B	-10.18B	-6.82B	-4.24B	-15.72B	-12.70B

Roche Holding Ltd Technical Analysis

Technical Analysis SentimentPositive

Last Price411.20

Price Trends

50DMA373.73Positive

100DMA362.07Positive

200DMA349.46Positive

Market Momentum

MACD11.15Negative

RSI77.35Negative

STOCH88.95Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:RO, the sentiment is Positive. The current price of 411.20 is above the 20-day moving average (MA) of 385.47, above the 50-day MA of 373.73, and above the 200-day MA of 349.46, indicating a bullish trend. The MACD of 11.15 indicates Negative momentum. The RSI at 77.35 is Negative, neither overbought nor oversold. The STOCH value of 88.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:RO.

Roche Holding Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

CH:RO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CH:GALD	80Outperform	CHF 44.97B	63.88	―	0.18%	15.78%	111.61%
CH:RO	73Outperform	CHF 321.78B	26.26	―	2.63%	-1.06%	30.86%
CH:BSLN	71Outperform	CHF 871.17M	16.62	―	―	4.74%	-28.96%
CH:NOVN	71Outperform	CHF 244.89B	31.19	―	2.77%	-4.48%	-33.14%
CH:SDZ	67Neutral	CHF 36.25B	67.02	7.04%	0.97%	0.81%	165.32%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
CH:IDIA	45Neutral	CHF 1.20B	-4.03	―	―	-5.32%	-95.96%

* General Sector Average

Performance Comparison

CH:RO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:RO	Roche Holding Ltd	411.20	147.82	56.12%
CH:NOVN	Novartis	133.78	37.22	38.54%
CH:BSLN	Basilea Pharmaceutica	70.80	25.50	56.29%
CH:IDIA	Idorsia Ltd	4.47	0.97	27.90%
CH:SDZ	Sandoz Group Ltd	82.38	27.68	50.62%
CH:GALD	Galderma Group AG	192.85	41.68	27.57%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 23, 2026

Roche Holding Ltd AI Stock Analysis